Caroline Peine, Anna Stoliaroff-Pepin, Ulrich Reinacher, Katharina Heldt, Giselle Sarganas, Vanessa Piechotta, Agata Mikolajewska, Antonia Pilic, Nina Barkowski, Daniel Bleve, Marie H Giebeler, Susanne Poser, Livia Searle, Elisabeth Kißner, Leonie Nitsche, Fatimanur Bayram, Waldemar Siemens, Annika Ziegler, Jörg J Meerpohl, Frank Sandmann, Ole Wichmann, Thomas Harder
{"title":"COVID-19疫苗对COVID-19后病情/长COVID的有效性：系统评价和荟萃分析","authors":"Caroline Peine, Anna Stoliaroff-Pepin, Ulrich Reinacher, Katharina Heldt, Giselle Sarganas, Vanessa Piechotta, Agata Mikolajewska, Antonia Pilic, Nina Barkowski, Daniel Bleve, Marie H Giebeler, Susanne Poser, Livia Searle, Elisabeth Kißner, Leonie Nitsche, Fatimanur Bayram, Waldemar Siemens, Annika Ziegler, Jörg J Meerpohl, Frank Sandmann, Ole Wichmann, Thomas Harder","doi":"10.1016/j.cmi.2025.07.026","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Persons infected with SARS-CoV-2 can develop long-term symptoms known as postCOVID-19 condition (PCC; symptoms ≥3 months after infection) or long COVID (LC; symptoms ≥1 month after infection). Vaccination against COVID-19 might prevent PCC/LC, but the extent of protection is unclear.</p><p><strong>Objectives: </strong>The aim of this systematic review was to evaluate the vaccine efficacy/effectiveness (VE) of COVID-19 vaccines given prior to SARS-CoV-2 infection in preventing PCC or LC.</p><p><strong>Methods data sources: </strong>Studies were identified in Embase, MEDLINE, PreView, COVID-19 L.OVE repository, and Cochrane Library up to August 1, 2024.</p><p><strong>Study eligibility criteria, participants, and interventions: </strong>Randomized controlled trials and nonrandomized studies of interventions (NRSI) that investigated immunization with a COVID-19 vaccine before SARS-CoV-2 infection were eligible, irrespective of participant age and sex.</p><p><strong>Assessment of risk of bias: </strong>Risk of bias was assessed using the ''Risk Of Bias In Nonrandomized Studies-of Interventions'' tool.</p><p><strong>Methods of data synthesis: </strong>Primary outcome was PCC, secondary outcomes were LC, time until reconvalescence, limitations in everyday activity, and quality of life. Meta-analyses were primarily conducted using the random-effects model.</p><p><strong>Results: </strong>A total of 6423 records were screened, and 65 NRSI reporting adjusted estimates were included, comprising >5.7 mio.</p><p><strong>Participants: </strong>VE for ≥1 vaccine dose against PCC was 41.0% (95% CI 27.8%; 51.7%; 22 NRSI, certainty of evidence: low). VE after 1, 2, or 3 doses versus unvaccinated was 19.1% (-119.4%; 70.2%, 3 NRSI), 43.2% (4.5%; 66.2%; 4 NRSI), and 70.0% (30.0%; 87.0%; 1 NRSI), respectively. In <18 years old, VE against PCC was 26% for ≥1 dose (-4%; 48%, 1 NRSI) and in >60 years old 41% (17%; 59%, 1 NRSI). VE after pre-Omicron-SARS-CoV-2 infection was 32.1% (-54.3%; 70.1%, 3 NRSI) and 20.9% (-10.1%; 43.3%, 2 NRSI) after Omicron infection. Sensitivity analyses indicated no influence of risk of bias and effect measure.</p><p><strong>Conclusions: </strong>COVID-19 vaccines may be moderately effective in preventing PCC/LC. VE may increase with the number of vaccine doses administered.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":8.5000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of COVID-19 vaccines against post-COVID-19 condition/long COVID: systematic review and meta-analysis.\",\"authors\":\"Caroline Peine, Anna Stoliaroff-Pepin, Ulrich Reinacher, Katharina Heldt, Giselle Sarganas, Vanessa Piechotta, Agata Mikolajewska, Antonia Pilic, Nina Barkowski, Daniel Bleve, Marie H Giebeler, Susanne Poser, Livia Searle, Elisabeth Kißner, Leonie Nitsche, Fatimanur Bayram, Waldemar Siemens, Annika Ziegler, Jörg J Meerpohl, Frank Sandmann, Ole Wichmann, Thomas Harder\",\"doi\":\"10.1016/j.cmi.2025.07.026\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Persons infected with SARS-CoV-2 can develop long-term symptoms known as postCOVID-19 condition (PCC; symptoms ≥3 months after infection) or long COVID (LC; symptoms ≥1 month after infection). Vaccination against COVID-19 might prevent PCC/LC, but the extent of protection is unclear.</p><p><strong>Objectives: </strong>The aim of this systematic review was to evaluate the vaccine efficacy/effectiveness (VE) of COVID-19 vaccines given prior to SARS-CoV-2 infection in preventing PCC or LC.</p><p><strong>Methods data sources: </strong>Studies were identified in Embase, MEDLINE, PreView, COVID-19 L.OVE repository, and Cochrane Library up to August 1, 2024.</p><p><strong>Study eligibility criteria, participants, and interventions: </strong>Randomized controlled trials and nonrandomized studies of interventions (NRSI) that investigated immunization with a COVID-19 vaccine before SARS-CoV-2 infection were eligible, irrespective of participant age and sex.</p><p><strong>Assessment of risk of bias: </strong>Risk of bias was assessed using the ''Risk Of Bias In Nonrandomized Studies-of Interventions'' tool.</p><p><strong>Methods of data synthesis: </strong>Primary outcome was PCC, secondary outcomes were LC, time until reconvalescence, limitations in everyday activity, and quality of life. Meta-analyses were primarily conducted using the random-effects model.</p><p><strong>Results: </strong>A total of 6423 records were screened, and 65 NRSI reporting adjusted estimates were included, comprising >5.7 mio.</p><p><strong>Participants: </strong>VE for ≥1 vaccine dose against PCC was 41.0% (95% CI 27.8%; 51.7%; 22 NRSI, certainty of evidence: low). VE after 1, 2, or 3 doses versus unvaccinated was 19.1% (-119.4%; 70.2%, 3 NRSI), 43.2% (4.5%; 66.2%; 4 NRSI), and 70.0% (30.0%; 87.0%; 1 NRSI), respectively. In <18 years old, VE against PCC was 26% for ≥1 dose (-4%; 48%, 1 NRSI) and in >60 years old 41% (17%; 59%, 1 NRSI). VE after pre-Omicron-SARS-CoV-2 infection was 32.1% (-54.3%; 70.1%, 3 NRSI) and 20.9% (-10.1%; 43.3%, 2 NRSI) after Omicron infection. Sensitivity analyses indicated no influence of risk of bias and effect measure.</p><p><strong>Conclusions: </strong>COVID-19 vaccines may be moderately effective in preventing PCC/LC. VE may increase with the number of vaccine doses administered.</p>\",\"PeriodicalId\":10444,\"journal\":{\"name\":\"Clinical Microbiology and Infection\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":8.5000,\"publicationDate\":\"2025-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Microbiology and Infection\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cmi.2025.07.026\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Microbiology and Infection","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cmi.2025.07.026","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Effectiveness of COVID-19 vaccines against post-COVID-19 condition/long COVID: systematic review and meta-analysis.
Background: Persons infected with SARS-CoV-2 can develop long-term symptoms known as postCOVID-19 condition (PCC; symptoms ≥3 months after infection) or long COVID (LC; symptoms ≥1 month after infection). Vaccination against COVID-19 might prevent PCC/LC, but the extent of protection is unclear.
Objectives: The aim of this systematic review was to evaluate the vaccine efficacy/effectiveness (VE) of COVID-19 vaccines given prior to SARS-CoV-2 infection in preventing PCC or LC.
Methods data sources: Studies were identified in Embase, MEDLINE, PreView, COVID-19 L.OVE repository, and Cochrane Library up to August 1, 2024.
Study eligibility criteria, participants, and interventions: Randomized controlled trials and nonrandomized studies of interventions (NRSI) that investigated immunization with a COVID-19 vaccine before SARS-CoV-2 infection were eligible, irrespective of participant age and sex.
Assessment of risk of bias: Risk of bias was assessed using the ''Risk Of Bias In Nonrandomized Studies-of Interventions'' tool.
Methods of data synthesis: Primary outcome was PCC, secondary outcomes were LC, time until reconvalescence, limitations in everyday activity, and quality of life. Meta-analyses were primarily conducted using the random-effects model.
Results: A total of 6423 records were screened, and 65 NRSI reporting adjusted estimates were included, comprising >5.7 mio.
Participants: VE for ≥1 vaccine dose against PCC was 41.0% (95% CI 27.8%; 51.7%; 22 NRSI, certainty of evidence: low). VE after 1, 2, or 3 doses versus unvaccinated was 19.1% (-119.4%; 70.2%, 3 NRSI), 43.2% (4.5%; 66.2%; 4 NRSI), and 70.0% (30.0%; 87.0%; 1 NRSI), respectively. In <18 years old, VE against PCC was 26% for ≥1 dose (-4%; 48%, 1 NRSI) and in >60 years old 41% (17%; 59%, 1 NRSI). VE after pre-Omicron-SARS-CoV-2 infection was 32.1% (-54.3%; 70.1%, 3 NRSI) and 20.9% (-10.1%; 43.3%, 2 NRSI) after Omicron infection. Sensitivity analyses indicated no influence of risk of bias and effect measure.
Conclusions: COVID-19 vaccines may be moderately effective in preventing PCC/LC. VE may increase with the number of vaccine doses administered.
期刊介绍：
Clinical Microbiology and Infection (CMI) is a monthly journal published by the European Society of Clinical Microbiology and Infectious Diseases. It focuses on peer-reviewed papers covering basic and applied research in microbiology, infectious diseases, virology, parasitology, immunology, and epidemiology as they relate to therapy and diagnostics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
